NRXP

TentativeAI Memo

NRX

As of 2026-10-21/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-21 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Preservative-free ketamine ANDA decision • 2026-11-10

Base target: $2 / p=45% prob

Biggest risk

Regulatory timing remains uncertain, the NRX-100 path is unfinished, and clinical expansion may require more capital. The 10-Q's going-concern disclosure outweighs management's more optimistic runway language until financing or cash generation improves. [#10-Q-2026-08-14] SEC 10-Q

Invalidation

Break below $1 or thesis failure.

What would change my mind?

A timely ketamine ANDA approval could turn completed manufacturing validation into a commercial launch, while the DARPA-funded study provides a distinct longer-term clinical opportunity.

Research note

Recommendation

—

Confidence

medium

As of

2026-10-21

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

NRX-101 SPARC-TMS enrollment
NRX-100 depression NDA progress
A timely ketamine ANDA approval could turn completed manufacturing validation into a commercial launch, while the DARPA-funded study provides a distinct longer-term clinical opportunity.

BearKey bullets

NRX-100's real-world-evidence strategy still requires a completed NDA and FDA review.
The June 2026 10-Q reported a $4.7 million working-capital deficit and substantial doubt about going-concern status; additional equity could dilute holders.
[#10-Q-2026-08-14] SEC 10-Q

WatchKey bullets

Preservative-free ketamine ANDA decision

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=45%)

Target spread vs base: +82% / -44%

Scenario probabilities

Bull Target: $4 (p=25%)Base Target: $2 (p=45%)Bear Target: $1 (p=30%)

Commentary

Recent company updates improve the near-term regulatory setup, but the supplied news coverage is thin and no verified post-update analyst revisions or market-reaction figures are available. The October 16 8-K sets an annual-meeting date, not an operating milestone. [#8-K-2026-10-16] SEC 8-K The deterministic prior is negative despite stronger primary-source coverage; this remains an event-driven monitoring view.

As of 2026-10-21 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

A timely ketamine ANDA approval could turn completed manufacturing validation into a commercial launch, while the DARPA-funded study provides a distinct longer-term clinical opportunity.

Bear Case

Drivers

Scannable catalysts and supporting factors

NRX-101 SPARC-TMS enrollment
NRX-100 depression NDA progress

Scenarios

Bull Target (Scenario probability)

$4 / p=25% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-10-21 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-10
Preservative-free ketamine ANDA decision
The company reports a November 10, 2026 FDA goal date. It says the latest labeling requests were minor and that three commercial-scale validation lots are complete. Approval and saleable launch remain unconfirmed. [#PR-2026-10-15] [#PR-2026-10-19] FDA labeling update Manufacturing update
Prob 55.00% • Move 35.00% • Priced-in 40.00%
EVENT2027-03-31
Cash runway and financing
The June 2026 10-Q reported $26.7 million of cash, $13.2 million of first-half operating cash use and substantial doubt about continuing as a going concern. Financing terms or reduced cash use by early 2027 could materially change dilution risk. [#10-Q-2026-08-14] SEC 10-Q
Prob 65.00% • Move -20.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

NRX-101 SPARC-TMS enrollment
2027-06-30
NRx announced an initial $11.18 million DARPA contract and said the NRX-101 plus robotic-TMS study would begin enrolling. Enrollment progress, funding conversion and eventual efficacy remain separate hurdles; a registration outcome is not established. [#PR-2026-09-30] Company announcement
Prob 50% • Move 20% • Priced-in 25%
NRX-100 depression NDA progress
2027-12-31
In its Q2 update, management said it was advancing the NRX-100 NDA using real-world evidence and aimed for a 2027 approval. A completed submission, FDA acceptance and approval are not yet verified. [#PR-2026-08-17] Company Q2 release
Prob 35% • Move 25% • Priced-in 20%

Risks

NRX-100's real-world-evidence strategy still requires a completed NDA and FDA review.
The June 2026 10-Q reported a $4.7 million working-capital deficit and substantial doubt about going-concern status; additional equity could dilute holders. [#10-Q-2026-08-14] SEC 10-Q
The November 10 date is an FDA review goal, not an approval commitment; labeling or manufacturing issues could still delay clearance.
The SPARC-TMS trial must enroll and demonstrate efficacy; a DARPA contract does not establish an approvable result.

Peers

Symbol	Summary
ENGN	Packet-selected small-cap biotechnology comparator by sector and market capitalization; no direct indication or operating overlap is established.
GNLX	Packet-selected small-cap biotechnology comparator by sector and market capitalization; useful only for broad clinical and financing-risk context, not a direct product comparison.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-21

Loading AI feed…

Symbol

Summary

ENGN

Packet-selected small-cap biotechnology comparator by sector and market capitalization; no direct indication or operating overlap is established.

GNLX

Packet-selected small-cap biotechnology comparator by sector and market capitalization; useful only for broad clinical and financing-risk context, not a direct product comparison.